AURO LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 51 | 53 | 54 | 19 | 31 |
| EBITDA (ex other income) | 5 | 4 | 11 | 3 | 10 |
| margin % | 9.1 | 8.3 | 19.9 | 17.6 | 32.1 |
| Owners' profit | 3 | 2 | 8 | 2 | 4 |
| EPS, as reported (₹) | 4.56 | 3.92 | 12.50 | 2.95 | 5.67 |
| ROE % · ROCE % | 9.0 · 13.5 | 7.1 · 11.3 | 18.6 · 17.9 | 4.3 · 3.8 | 7.6 · 9.8 |
| Debt / equity (x) | 0.41 | 0.18 | 0.63 | 1.05 | 1.37 |
| Cash from operations | (7) | 3 | 19 | 6 | 2 |
| Capex | (5) | (4) | (36) | (24) | (57) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 3 | 3 | 7 | 3 | 9 | 9 | 10 |
| Profit before tax | 1 | 0 | 0 | 0 | (0) | 2 | 2 | 1 |
| Net profit | 1 | 0 | 0 | 0 | (0) | 1 | 2 | 1 |
| EPS (₹) | 1.21 | 0.57 | 0.08 | 0.63 | 0.17 | 1.15 | 3.13 | 1.56 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 17 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 13 Aug 2026 · 37th AGM Scrutinizer Report - All 4 Resolutions Passed with 100% Approval | compliance | minimal | — | — |
| 11 Aug 2026 · Auro Laboratories 37th AGM concludes, 4 resolutions passed | board shareholder meetings | medium | — | — |
| 10 Aug 2026 · Board meeting on Aug 14, 2026 to approve Q1 FY27 results | results | low | — | — |
| 20 Jul 2026 · 37th AGM notice and e-voting info published in newspapers | compliance | minimal | — | — |
| 16 Jul 2026 · Annual Report FY 2025-26 web-link sent to shareholders; 37th AGM on Aug 11, 2026 | compliance | minimal | — | — |
| 16 Jul 2026 · Annual Report FY 2025-26 and 37th AGM Notice | compliance | medium | — | — |
| 16 Jul 2026 · 37th AGM Notice on August 11, 2026 - Financial Results and Director Reappointment | board shareholder meetings | low | — | — |
| 15 Jul 2026 · Quarterly dematerialisation certificate filed with BSE for Q1 FY27 | compliance | minimal | — | — |
| 15 Jul 2026 · Auro Laboratories fixes 37th AGM on August 11, 2026 via video conference | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| CIPLA LTD |
| 1,10,352 |
| 32.7 |
| 3.20 |
| 16.9 |
| 11.2 |
| 14.7 |
| 8.0 |
| 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 42.9 | 28.9 | 118 of 169 | 30% |
| P/B | 3.5 | 3.3 | 88 of 163 | 46% |
| ROCE | 5.2 | 10.8 | 122 of 183 | 34% |
| ROE | 7.6 | 10.4 | 107 of 171 | 38% |
| Debt / Equity | 1.4 | 0.1 | 163 of 171 | 5% |
| EBITDA margin | 39.1 | 17.5 | 10 of 165 | 95% |
| Revenue growth | 32.9 | 16.3 | 42 of 161 | 74% |
| Profit growth | 146.3 | 30.9 | 30 of 158 | 82% |
| Market cap | 160 | 839 | 123 of 182 | 33% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
